|
|
|
The 9th Annual Biological Production Forum 2010 |
World Trade Group |
|
21-23 June 2010
Frankfurt, Germany
This event focuses on both upstream and downstream processing for biological manufacturing, production and cGMP specialists. Over the course of this three day event, you will take part in a mixture of networking and conference session featuring the latest strategies and industry case studies. Included in the event this year is the opportunity to take part in a tour at Merck KGaA’s headquarters. It is a unique day which will give delegates the chance to be one of the first to tour their brand new Process Solutions and also learn about the latest advancements taking place there.
www.biologicalproduction.com
Event Organiser: World Trade Group
Contact person: Emilie Oliveira, Marketing Manager |
|
|
|
|
|
|
|
 |
Industry Events |
 |
BioPartnering North America™
26-28 February 2012, Vancouver Convention Centre, Vancouver, BC, Canada
BioPartnering North America 2012 (BPN) in Vancouver, Canada brings together senior executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to start-up.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
